Sector News

Lonza buys InterHealth in health push

August 15, 2016
Energy & Chemical Value Chain

Swiss specialty chemicals and pharmaceutical ingredients company Lonza has announced a deal worth up to $300 million to buy InterHealth Nutraceuticals, a developer and manufacturer of nutritional ingredients used in dietary supplements.

Lonza said the California company’s range of products like UC-11 to promote healthy joints would complement its own in sports nutrition, weight management, immune and pet health.

“With this acquisition Lonza is taking a further step along our strategic path as a high-value supplier to the healthcare continuum,” Chief Executive Richard Ridinger said in a statement, adding that the deal also boosted Lonza’s offerings in cognitive and diabetes health.

The consultancy KPMG has forecast that the nutraceuticals market will be worth $280 billion in 2018, a factor that it expects will prompt a wave of mergers and acquisitions.

Swiss food giant Nestle is among companies that have shown an increasing interest in health foods, hiring a new CEO from German medical company Fresenius and investing in firms whose products are meant to restore a healthy bacterial balance in the gut.

GLOBAL ROLLOUT

Ridinger said Lonza would sell Interhealth’s products globally and use the U.S. company’s network to distribute the Swiss firm’s existing product range.

“Lonza has succeeded in making an important step in expanding its product portfolio into the attractive area of nutritional ingredients,” said Zuercher Kantonalbank analyst Philipp Gamper. “This area promises above average growth and good margins with less cyclical volatility.”

The Swiss company, which also makes products like drinking water sanitizers and preservatives for industrial applications, currently generates nearly 42 percent of its sales from pharmaceutical and biotech products.

But the nutraceuticals area is faster growing and more profitable than Lonza’s specialty ingredients business, which makes ingredients that go into consumer care products.

By John Revill

Source: Reuters

comments closed

Related News

March 24, 2024

Thomas Gangl leaves Borealis

Energy & Chemical Value Chain

Appointed Borealis CEO in 2021, Thomas has led key initiatives including the sale of the nitrogen business, acquisitions of Rialti Spa and Integra Plastics AD, and Borouge’s IPO. He also made the final investment decision for the Borouge 4 plant, set to be the world’s largest polyolefin complex.

March 24, 2024

Chemours names Dignam permanent CEO

Energy & Chemical Value Chain

The Chemours Co. today named interim CEO Denise Dignam as the company’s permanent CEO and president, as well as a member of the board of directors, effective immediately. Dignam has been interim CEO since late February, when former CEO Mark Newman was placed on leave due to an internal investigation.

March 24, 2024

Neste merges three business lines into new Renewable Products unit

Energy & Chemical Value Chain

Neste Corp. (Espoo, Finland) has completed its organizational change process, announced on 1 November 2023. Neste informed that it will merge its three renewable business units into one Renewable Products business unit as well as restructure its functions to better support business-driven ways of working.

How can we help you?

We're easy to reach